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Ferric ion binding proteins (Fbps) transport FeIII across the periplasm and are vital for the virulence of many Gram negative
bacteria. Iron(III) is tightly bound in a hinged binding cleft with octahedral coordination geometry involving binding to protein
side chains (including tyrosinate residues) together with a synergistic anion such as phosphate. Niobium compounds are of
interest for their potential biological activity, which has been little explored. We have studied the binding of cyclopentadienyl
and nitrilotriacetato NbV complexes to the Fbp from Neisseria gonorrhoeae by UV-vis spectroscopy, chromatography, ICP-OES,
mass spectrometry, and Nb K-edge X-ray absorption spectroscopy. These data suggest that NbV binds strongly to Fbp and that a
dinuclear NbV centre can be readily accommodated in the interdomain binding cleft. The possibility of designing niobium-based
antibiotics which block iron uptake by pathogenic bacteria is discussed.
1. Introduction
Following the therapeutic success of cisplatin, a large number
of complexes of other metals have been studied. Nonplat-
inum complexes are of particular interest since they may
display a lack of cross-resistance with cisplatin, bringing
significant benefits for chemotherapy. Metallocene dihalides
and pseudohalides of general formula [Cp2MX2] (M = Ti,
V, Nb, Mo; X = F, Cl, Br, I, CN, SCN; Figure 1(a)), have
attracted significant interest since they have shown activity
towards a wide variety of murine and human tumors [1–9].
Titanocene dichloride [Cp2TiCl2] was the first non-platinum
metal complex to enter clinical trials but was eventually
abandoned owing to its high reactivity in aqueous solution
which gives rise to formulation diﬃculties [10, 11].
Vanadocene-, molybdenocene-, and niobocene dichlo-
rides also exhibit good activities. Niobocene dichloride
(Cp2NbCl2) is an extremely potent cancerostatic agent
against the Ehrich ascites tumour in CFI mice [12, 13].
Oxidation to NbV reduces the tumor inhibiting properties
[14] but potentially could also reduce toxic eﬀects. Hence
there is interest in further investigation of the biological
chemistry of niobium complexes [15].
Iron is the single most important micronutrient for
bacterial survival; it plays important roles in both pathogen
virulence and host antimicrobial resistance [16–18]. Numer-
ous pathogenic bacteria such as Neisseria gonorrhoeae and
Haemophilus influenzae have evolved a specific protein-
dependent iron-uptake system which can obtain iron from
the host transferrin (Tf) and lactoferrin (Lf). The three-
component system is a member of the ABC-transporter
super-family (FbpABC) and critical for iron uptake is a ferric
ion-binding protein (FbpA, referred to here as Fbp, a single-
chain 34 kDa protein) which shuttles FeIII across the periplas-
mic space, transporting FeIII from the outer membrane to the
cytoplasmic membrane [19]. This essentiality for virulence
makes Fbp an ideal drug target and provides a basis for
the design of novel metal-based antibiotics which combat
resistance to widely used organic antibiotics.
Structural analysis of the FeIII binding site in Fbp
from various bacteria has shown several diﬀerent classes
(Figure 1(b) shows the best characterised). All have a pair
of highly conserved Tyr residues in the active site and
the other metal binding residues are composed of amino
acid side chains (glutamate and histidine) and anions (e.g.,
phosphate). These tyrosines are critical for strong metal
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Figure 1: (a) Metallocene dihalides with antitumor activity. Key: (M) = maximum activity; M = sporadic activity; M = no activity. (b) FeIII
binding sites in bacterial ferric ion-binding proteins (Neisseria gonorrhoeae or Haemophilus influenzae).
ion binding, as confirmed by site-directed mutagenesis and
crystal structures of reconstituted Fbp protein complexes
with FeIII. These bacterial Fbps display an extremely high
aﬃnity for ferric iron (KD ∼ 1 × 10−20 M) but they also
have the capacity to bind other metals. We discovered that
N. gonorrhoeae Fbp could bind Ti, ZrIV, or HfIV in the metal
binding cleft [20–22]. Moreover, besides binding a single
metal ion we observed various metal clusters bound in an
adaptable active site which appears to be able to accommo-
date a wide range of metals ions and anions. To further probe
the specificity of this site we report for the first time studies
of the binding of NbV complexes to Fbp, using a wide variety
of techniques including UV-visible spectroscopy, inductively
coupled plasma atomic emission spectroscopy (ICP-AES),
electrospray mass spectrometry, and EXAFS. These studies
are important not only for exploring a potential mechanism
for niobium transport but also as a basis for the possible
design of novel metalloantibiotics.
2. Experimental/Materials and Methods
2.1. Materials. [Cp2NbCl2] (Arcos), monosodium citrate
(Aldrich), nitrilotriacetic acid (H3NTA, 99%, Aldrich, N840-
7), NaH2PO4 and Na2HPO4 (BDH), Hepes (Aldrich), Tris
(Aldrich), and cetyltrimethylammonium bromide (CTAB,
Aldrich) were used as received. Atomic absorption stan-
dard solutions of Fe (Aldrich, cat: 30595-2), Nb (1000
ppm, niobium(V) chloride in 4% hydrofluo, VWR interna-
tional Ltd. Cat: 1026410100), and P (Aldrich, cat: 20735-7)
were used as supplied.
All other chemicals were reagent grade and used as
provided.
Stock solutions of [FeIII(NTA)2]3− and [Nb
V(NTA)n]
were prepared from iron and niobium atomic absorption
standard solutions and stoichiometric amounts of H3NTA.
The pH values of the solutions were raised slowly to∼5.6 and
5.26, respectively, with microliter amounts of NaOH (1 M).
The [Cp2Nb(OH)Cl2] stock solution was freshly pre-
pared by sonication of [Cp2NbCl2] (2.9 mg, 0.099 mmol)
in D2O (0.5 mL) until no solid remained (typically 0.5–
1 h). As [Cp2NbCl2] is insoluble in water, oxygen was
required [22] to eﬀect oxidation to the water-soluble nio-
bium(V) complex [Cp2Nb(OH)Cl2] [14]. Finally a yellow
solution of [Cp2Nb(OH)Cl2] was obtained. This solution
may also contain other hydrolysed Cp2Nb
V species as
well as small amounts of hydrolysed NbIV species such as
[Cp2NbCl(H2O)]+.
Electrophoresis was carried out using a Bio-Rad ProteinII
Minigel system (protein) and Invitrogen H5 system (DNA).
GE Healthcare AKTA equipment and columns were used for
chromatographic separations of proteins. Precast SDS-PAGE
gels (10% bis-Tris) were purchased from Invitrogen and used
according to the manufacturer’s instructions.
2.2. Overexpression and Purification of Fbp. Fbp was overex-
pressed in E. coli TOP10 One Shot or DH5α cells (Invitrogen)
transformed with the plasmid pTrc99A/Fbp/Ng. A single
colony from freshly transformed cells was used to inoculate
5 mL of 2YT broth which contained 100 μg/mL ampicillin
in a sterile 10 mL vial. This culture was shaken overnight
at 310 K and used to inoculate 3 liters of 2YT broth with
100 μg/mL ampicillin in sterile 500 mL flasks. After the
flasks were shaken overnight at 310 K, a pink cell pellet was
harvested by centrifugation at 10, 000 × g for 15 minutes at
277 K and stored at 253 K until use.
Fbp was purified by a modification of the method
reported previously [20, 22, 23]. The pink pellet (∼15 g) was
defrosted at room temperature and resuspended in 150 mL of
50 mM Tris (pH 8.0) containing 2% cetyl trimethylammo-
nium bromide (CTAB), sonicated for 5 minutes (30 second
on, 30 s oﬀ), followed by stirring slowly overnight at 310 K.
The white insoluble material was removed by centrifugation
at 10, 000 × g for 15 minutes at 277 K. The supernatant
(cell-free extract) was dialysed against 5000 mL 10 mM Tris
(pH 8.0) at room temperature overnight, followed by the
dialysis for another 3 hours to remove CTAB and then filtered
using Whatman paper (0.2 μm, Fisher). The cell-free extract
was applied to a RESOURCE S strong cation exchange
column (6 mL, Amersham Biosciences); the column was
equilibrated with 10 mM Tris buﬀer (pH 8.0). Unbound
proteins were removed by extensive washing with low salt
buﬀer. The target protein (Fbp) was then eluted with a
linear NaCl gradient of low-to-high salt (0-1 M NaCl) over
20 column volumes in 10 mM Tris buﬀer. Pink fractions
were collected and were analyzed by SDS-PAGE. Fbp was
desalted by dialysis and concentrated by ultrafiltration
(10 kDa cut-oﬀ, Amicon concentrator). The concentration
of purified iron-bound, holo-Fbp protein was determined
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by UV absorption using ε481 = 2, 430 M−1 cm−1, or ε280 =
48, 900 M−1 cm−1[24]
2.3. Preparation of Apo-Fbp. Iron-free, apo-Fbp was pre-
pared by treatment of holo-Fbp solutions with 250 mM
sodium citrate (pH 4.5) at room temperature for 5 hours,
followed by elution with 250 mM sodium citrate (pH 4.5)
on a PD-10 column (GE Healthcare), so as to give negligible
absorbance at 481 nm. The apo-Fbp was then washed 6 times
with 0.1 M KCl in a Centricon YM-30 microconcentrator
(Amicon), and the stock solution was stored at 4◦C before
use. apo-Fbp concentration was determined with ε280 =
44,270 M−1 cm−1 [24].
2.4. UV-Visible Spectroscopy. All UV experiments were per-
formed with 1 cm cuvettes on a computer-controlled Cary
300 spectrometer with temperature control at 298 or 310 K.
For kinetic experiments, the time courses for the reactions of
apo-Fbp (10 μM) with 2 mol equivalent of [Cp2Nb(OH)Cl2]
or [Nb(NTA)2]− were recorded for solutions in Hepes buﬀer
(10 mM, pH 7.4) at 310 K. UV/Vis spectra were recorded at 5
minutes intervals against the same buﬀer solution containing
the same amount of [Cp2Nb(OH)Cl2] or [Nb(NTA)2]− in
the reference cuvette.
First-order rate constants, kobs, were calculated by fitting
plots of absorbance at 245 nm versus time to (1) using the
program Origin7.5, whereA,A0, and A∞ are the absorbances
at time t, time zero, and after infinite time:
log(A∞ − A) = −kobst + log(A∞ − A0). (1)
For titration experiments, solutions were prepared by dilut-
ing aliquots of a stock apo-Fbp solution to ∼10 μM with
10 mM Hepes buﬀer, 5 mM phosphate, pH 7.4. Aliquots of
metal complex (0.5–10 μl) were added, and each solution
was allowed to equilibrate at 310 K for 1 hour before the
spectrum was recorded.
The displacement of metal ions from the protein was
also monitored by adding aliquots of 1 : 50 Nb : NTA to
(iron-bound) holo-Fbp in the above buﬀer at 310 K. UV-
visible spectra were recorded half an hour after each addition.
Buﬀers containing the same amount of 1 : 50 Nb : NTA were
used as references. The binding or release of FeIII was
monitored by the increase or decrease in absorbance at
481 nm.
2.5. Chromatographic Analysis. For chromatographic analy-
sis, the Nb-Fbps were prepared by reacting apo Fbp with
20 mol equiv of freshly prepared Cp2NbCl2 (bubbled with
air, as oxygen is required to eﬀect oxidation to the water solu-
ble niobium(V) complex Cp2Nb(OH)Cl2) or [Nb(NTA)2]−
for 48 hours at 310 K in 10 mM Hepes buﬀer, pH 7.4. Small
molecules (<30 kDa) were removed by ultrafiltration using
0.1 M KCl, and then the sample was applied to a Mono
S HR5/5 column equilibrated with Hepes buﬀer (10 mM,
pH 7.4, 25 mL), followed by gradient elution with 0-1 M
KCl in Hepes (10 mM; pH7.4) flow rate 0.5 mL min−1. Peak
fractions were collected and pooled, and then subjected to
ultrafiltration (Centricon, 30 kDa cut oﬀ, YM-30, Millipore)
to remove NaCl.
2.6. ICP-OES Analysis. ICP-OES was performed on Perkin
Elmer Optical Emission Spectrometer Optima 5300DV using
standard methods. Metal-loaded proteins were prepared
using the same chromatographic procedures as for holo-
Fbp isolation, collected and purified by using Centricon 30
(Amicon) ultrafiltration and washing six times with ultra-
pure water followed by ultrafiltration after each washing.
The protein solution was finally diluted with ultrapure water.
The contents of Nb and S were measured, after digestion
of the samples, using the emission lines of 309.418 nm and
181.975 nm for Nb and S, respectively.
2.7. Mass Spectrometry. Samples Nb-Fbps for ESI-MS
were prepared by reacting a 20-fold molar excess of
[Cp2Nb(OH)Cl2] or [Nb
V(NTA)2] with apoFbp (ca.
0.5 mM) in 10 mM HEPES buﬀer pH 7.5 in a water bath
at 310 K for 48 hours. Unbound NbV complexes were
removed from the protein by ultrafiltration (Centricon 30,
cut-oﬀ 30 kDa, Amicon) washing with 0.1 M KCl and H2O
three times, respectively, and then exchanged into a 10 mM
NH4Ac buﬀer (pH 8.0) by using a PD-10 column.
Positive-ion electrospray mass spectrometry was per-
formed on a Micromass Platform II quadruple mass
spectrometer equipped with an electrospray ion source.
The purified holo-Fbp, apo-Fbp, or recombinant Nb-Fbp
samples in 10 mM NH4Ac buﬀer (pH 8.0) were diluted
with CH3CN/H2O (1 : 1, v/v) to a final concentration of
25 μM. Each sample was infused at 50 μL/minute directly into
the mass spectrometer, and the ions were produced in an
atmospheric pressure ionization (API)/ESI ion source. The
spray voltage was 3.50 kV. The cone voltage was varied from
20 to 60 V as required. The capillary temperature was 338 K
for direct infusion, with a 450 L h−1 flow of nitrogen drying
gas. The quadrupole analyzer, operated at a background
pressure of 5.9 × 10−5 mBar, was scanned at 200 Da s−1 for
direct infusion. Data were collected (for 10 scans during the
direct infusion assays) and analyzed on a Mass Lynx (ver.3.5).
The deconvoluted average molecular mass was determined
using the MaxEnt and Transform algorithms of massLynx
software.
2.8. X-Ray Absorption Spectroscopy. X-ray spectra were
recorded at the niobium K edge on EXAFS station 16.1
at Daresbury Laboratory Synchrotron Radiation Source
(operating at 2 GeV) using an Si 〈220〉 double crystal
monchromator and vertically focusing mirror for harmonic
rejection. Data for apo-Fbp loaded with NbV were collected
at 13 K (using a liquid helium cryostat) in fluorescene mode
using a 13-element solid state germanium detector. Data
were collected in k space using a k3-weighted regime for
counting time with a total scan time of 40 minutes. 40
scans were collected from each sample. The edge positions
were calibrated against an Nb foil. Samples were prepared
as follows. Purified native Fbp was concentrated to 5 mM by
ultrafiltration and washed six times with 0.1 M KCl. Nb-Fbp
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(1 mM) was prepared by reacting apo-Fbp with 10 mol eq
of Cp2Nb(OH)Cl2 in Hepes buﬀer (pH 7.4). The excess of
[Cp2Nb(OH)Cl2] was removed from the yellowish solution
by ultrafiltration, washing three times with 0.1 M KCl and
then ultrapure water.
Data were processed using EXCALIB and SPLINE (mod-
ified for use with EXCURV) [25]. The EXAFS data were con-
verted into k space and analyzed using the fast curved wave
(or Rehr-Albers) theory [26] including up to third-order
multiple scattering contributions in EXCURV98 [27]. Phase
shifts were calculated using Hedin-Lundquist exchange and
correlation potentials [28, 29] and tested against the EXAFS
data for [Cp2NbCl2] and NbCl5. All the data analysis was
conducted on raw EXAFS data (without Fourier filtering)
weighted by k3 to compensate for diminishing amplitude at
high k.
3. Results and Discussion
3.1. Characterization of Fbp. Since Fbp contains an N-
terminal signal sequence that directs Fbp to the periplasmic
space, the overexpressed protein was located in the periplasm
of E. coli. The molecular masses of holo-Fbp and apo-
Fbp determined by electrosprary mass spectrometry were
33,640 Da, in good agreement with the amino acid sequence
(309 amino acids, without iron or phosphate theoretical
mass of 33639.39 Da). This suggests that, under the condi-
tions used for mass spectrometry, neither holo-Fbp nor apo-
Fbp had iron or synergistic anion bound to the protein and
that the Fbp signal sequence had been cleaved at Asp23 upon
translocation to the periplasm. The presence of iron in holo-
Fbp was evident from the ligand-to-metal charge-transfer
(LMCT) (tyrosinate-to-FeIII) band of FeIII-Fbp (vide infra).
For metal binding experiments, iron was eﬃciently removed
by incubation with excess citrate to generate apo-Fbp with
no detectable iron remaining.
3.2. Rate and Stoichiometry of Nb Binding to ApoFbp. The
time-courses of reactions between apoFbp and [NbV(NTA)2]−
(we use this formulation for solutions containing NbV
and 2 mol equiv of NTA) or [Cp2Nb
V(OH)Cl2] were
studied using UV/Vis spectroscopy. Two molar equivalents
of [NbV(NTA)2]− or [Cp2Nb
V(OH)Cl2] were added to a
solution of apoFbp (∼10 μM, in 500 μL 10 mM Hepes buﬀer,
5 mM phosphate, pH 7.4) at 310 K.; typical spectra are shown
in Figures 2 and 3, respectively. In the case of [NbV(NTA)2],
the reaction produced a UV diﬀerence spectrum which
is similar to reactions of other metal ions with apoFbp
[20, 30]; two new positive bands appeared at ca. 245 and
295 nm, and increased in intensity over a period of 60
minutes (Figures 2(a) and 2(b)). These bands are assignable
to π-π∗ transitions of Tyr residues deprotonated by binding
to NbV. Similar bands are seen when both bacterial and
serum transferrins bind to a wide variety of metal ions
[31–33]. This suggests that NbV ions can occupy specific
FeIII binding sites. Best fits to the data were obtained using
first-order kinetics equations, although the rate law was
not investigated. The first-order rate constant, kobs, was
3.03±0.01 h−1 (310 K), and the extinction coeﬃcient (Δε245)
reached ca. 15200 M−1 cm−1(Figure 2(c)).
In the case of [Cp2Nb
V(OH)Cl2], the reaction produced
two new bands in the UV/Vis spectra; one broad band is
centred at around 320 nm. The other sharp band is at ca.
244 nm (Figure 3(a)). The reaction was complete in ca. 2
hours (Figures 3(a), 3(b) and 3(c)). Kinetic studies revealed
kobs of 1.24± 0.03 h−1 (310 K), and the extinction coeﬃcient
(Δε244) reached ca. 16700 M−1 cm−1 (Figure 3(d)). These
data indicate that the reactions occur in two kinetic phases;
however, the initial phases of the reactions of apoFbp
with [Nb(NTA)2]− and [Cp2Nb
V(OH)Cl2] were fast (within
1 hour and 2 hours, resp.).
Analysis of the titration curves for the reaction of apoFbp
with [Nb(NTA)2]− and [Cp2Nb(OH)Cl2] (Figures 2(d) and
3(e)) suggests that about two NbV ions bind strongly to Fbp
in both cases. In these experiments, each sample was allowed
to equilibrate for 2 hours after each addition and then UV
diﬀerence spectra were recorded. The absorptivity Δε244/245
increased linearly with increase in molar ratio r[Nb]/[apoFbp]
until a value of ca. r = 2. Beyond r = 2, the titration
curve reached a plateau (Figures 2(d) and 3(e)). Titration
studies suggested that a niobium : protein molar ratio of 2 : 1
is suﬃcient to deprotonate both Tyr 195 and Tyr 196 when
phosphate is present as the synergistic anion; phosphate is
known to bind in the interdomain cleft of the apo-protein
and may prepare the cleft for metal entry [34]. Beyond a
2 : 1 [Nb] : [apoFbp] ratio there was little increase in the
absorption at 244 or 245 nm (Figures 2(d) and 3(e)). These
data suggest that the initial reaction with apo-Fbp involves
NbV binding to Tyr 195 and Tyr 196 either initially as a
mononuclear niobium centre binding to one of the Tyr
side-chains followed by subsequent binding of the second
niobium to the second Tyr and formation of an oxo-niobium
dinuclear center or perhaps by direct uptake of a dinuclear
species which may involve one NbV binding to both Tyr
residues or one to each. Hence there is little increase in the
absorption at 241 nm beyond a 2 : 1 [Nb] : [apoFbp] ratio. In
particular, the mobility of Tyr 196 (as observed in crystals
of oxo-FeIII-Fbp) [22] may be important for capturing NbV
ions at the protein surface and delivering them into the
binding cleft. In our previous studies of the binding of
trinuclear FeIII, HfIV (also pentanuclear HfIV), and ZrIV oxo-
clusters to Fbp, we have observed anchoring of these centres
via these tyrosinates with each binding to diﬀerent metals (or
in the case of one FeIII cluster, anchoring via a single Tyr)
[20, 22, 35]. It appears that the other two protein ligands,
His 9 and Glu 57 are not essential for the initial steps of metal
binding in vitro.
3.3. Displacement of FeIII from Fe-Fbp by NbV . To confirm
that NbV binds to the specific FeIII-binding sites of Fbp/Ng,
we investigated the displacement of FeIII from holo-Fbp
(FeIII-phosphate-Fbp) by NbV. Holo-Fbp was saturated with
Fe3+ by incubating apoFbp (100 μM) with 10 mol equivalent
1 : 2 Fe : NTA in 10 mM Hepes, 5 mM phosphate, pH 7.4,
310 K for 24 hours. After removing unbound Fe and
diluting the Fe-Fbp solution to 25 μM, 1.0 mol equivalent
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Figure 2: (a) UV diﬀerence UV/Vis spectra recorded at various times during the reaction of apoFbp (10 μM) with 2.0 mol equivalents of
[Nb(NTA)2]− in 10 mM Hepes buﬀer, 5 mM phosphate, pH 7.4, 310 K. (b) Time course for reactions of apo-Fbp (ca. 10 μM) with 2 mol
equivalents of [Nb(NTA)2]− in the 10 mM Hepes buﬀer, 5 mM phosphate, pH 7.4, 310 K, as a plot of molar absorptivity versus time for
reaction. (c) Diﬀerence UV/Vis spectra for the titration of apoFbp (10 μM) with [Nb(NTA)2]− in 10 mM Hepes buﬀer, 5 mM phosphate,
pH 7.4, 310 K (1 h equilibration). Molar ratios of Nb-complexes: apo-Fbp from bottom to top: are 0–2.0 in 0.2 mol equivalent steps, then
2.5, 3.0, 3.5, 4.0. (d) Titration curve for the reaction in (C), and Δε is the absorbance at 245 nm divided by the Fbp concentration.
of [Nb(NTA)2]− was added to the holo-Fbp solution in
physiological buﬀer at 310 K. There was no obvious change
to the LMCT band of FeIII-Fbp at 465 nm (Figure 4, insert).
In contrast, with the addition of 1 : 50 Nb : NTA, this band
decreased in intensity to about half of its original value
at the mol ratio of r[Nb]/[Fe-Fbp] of 10, and to about 21%
when r[Nb]/[Fe-Fbp] is 33 (Figure 4). It can be seen from the
graph that the wavelength of the absorption maximum of
the LMCT band shifted from 480 nm to 465 nm during
this titration. This suggests that under these conditions
phosphate is displaced form iron [30] and that NbV can
compete with FeIII for binding to Fbp, perhaps with initial
formation of mixed-metal oxo-Fe/Nb species in the binding
cleft.
3.4. Displacement of NbV from Nb2-Fbp by Fe
III . We also
investigated the displacement of NbV from Nb-Fbp by FeIII.
Nb-Fbp was prepared by incubating apo-Fbp (100 μM) with
10 mol equiv equivalent 1 : 2 Nb : NTA in 10 mM Hepes,
5 mM phosphate−, pH 7.4, 310 K for 24 hours, and FeIII-
binding was monitored by the appearance of the FeIII-Fbp
LMCT band at 465–480 nm. Nb-Fbp was titrated with 0.2–
10 mol equiv 1 : 2 Fe : NTA in the same buﬀer solution at
the same temperature. UV diﬀerence spectra were recorded
0.5 hours after each addition of FeIII. A peak centred at ca.
465 nm appeared and increased after 1.2 mol equiv of 1 :
2 Fe : NTA had been added, at which point it had almost
reached its final intensity and no further increase occurred
with 10 mol equiv FeIII present (Figure 5). Therefore, under
6 Bioinorganic Chemistry and Applications
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Figure 3: (a) Diﬀerence UV/Vis spectra recorded at various times during the reaction of apoFbp (9.8 μM) with 2.0 mol equivalents of
[Cp2Nb(OH)Cl2] in 10 mM Hepes buﬀer, 5 mM phosphate, pH 7.4 (b) Time course for reactions of apo-Fbp (ca. 9.8 μM) with 2 mol
equivalents of [Cp2Nb(OH)Cl2] in 10 mM Hepes buﬀer, 5 mM phosphate, pH 7.4, 310 K, as a plot of molar absorptivity versus time of
reaction. (c) Time course for reactions of apo-Fbp (ca. 9.8 μM) with 2 mol equivalents of [Cp2Nb(OH)Cl2] in the 10 mM Hepes buﬀer,
5 mM phosphate, pH 7.4 at 310 K as a plot of molar absorptivity versus time of reaction. (d) Diﬀerence UV/Vis spectra for the titration of
apoFbp (9.8 μM) with [Cp2Nb(OH)Cl2] in 10 mM Hepes buﬀer, 5 mM phosphate, pH 7.4, 310 K (2 h equilibration). Molar ratios of Nb-
complexes: apo-Fbp from bottom to top: are 0–2.0 in 0.2 mol equivalent steps, then 2.5, 3.0, 3.5, 4.0. (e) Titration curve for the reaction in
(D), Δε is the absorbance at 244 nm divided by the Fbp concentration.
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the conditions studied here, FeIII can displace NbV from the
protein.
3.5. Characterization of Nb-Fbp by Ion Exchange Chromatog-
raphy and ICP-OES Analysis. The products from reaction of
apoFbp with 20 molar equiv of freshly prepared [Cp2NbCl2]
(bubbled with air (oxygen) to obtain the water soluble
niobium(V) complex [Cp2Nb(OH)Cl2]) or [Nb(NTA)2]−
are at 310 K in Hepes buﬀer (10 mM, pH 7.4) for 48
hours. Unbound Nb was removed by extensive ultrafiltration
and the sample was applied to a cation exchange Mono
S HR5/5 column equilibrated with Hepes (10 mM; pH
7.4, 25 mL), followed by gradient elution with 0-1 M KCl
in Hepes (10 mM; pH 7.4) flow rate 0.5 mL min−1. The
chromatograms are shown in Figure 6. We observed two
peaks that elute at diﬀerent KCl concentrations which we
assume to be the diﬀerent forms of Nb-Fbp with diﬀerent
charges. It seems likely that the products from these loading
reactions contain diﬀerent multinuclear forms of Nb-Fbp.
Reaction of Fbp with 1 and 20 mol equivalents of
[Cp2Nb(OH)Cl2] gave products containing an average of
0.86 and 2.23 mol Nb per mol protein, respectively (ICP-OES
data; see Table 1). In the case of reactions with 1 and 20 mol
equivalents of [Nb(NTA)2]− under the same conditions,
the products contained ca. 0.91 and 2.41 mol Nb per mol
protein.
3.6. Electrospray Ionization Mass Spectroscopy (ESI-MS). The
recombinant protein, prepared as described in experimental
section, was further studied by electrospray ionization mass
spectrometry. The products were investigated as dilute
solutions in 10 mM NH4Ac, pH 8.0. For the reaction of
[Cp2Nb(OH)Cl2] with apoFbp, peaks centred at mass 34813,
34829, 34842, 34871, and 34890 are tentatively assigned to
[aFbp + 4Cp2NbCl2], [aFbp + 4Cp2NbCl2+ OH−], [aFbp
+ 4Cp2NbCl2 + 2OH−], [aFbp + 4Cp2NbCl2 + 3OH−],
and [aFbp + 4Cp2Nb(OH)Cl2], respectively. Another sample
prepared from apoFbp and [Nb(NTA)2]− gave peaks centred
at mass 34655, 34837, and 34965 corresponding to [aFbp
+ NH+4 ], [aFbp + 2Nb(NTA)2 + CH3COO
−], [aFbp +
3Nb(NTA)2 + NTA]. Table 2 contains a list of the species
observed by ESI-MS assays of Nb-Fbp. These results indicate
that apoFbp binds NbV tightly under the conditions used
and suggests that the binding cleft can accommodate not
only a single metal ion but also multinuclear Nb species,
as observed previously for iron, zirconium and hafnium.
However, these data alone do not rule out the possible
presence of Nb binding sites elsewhere on the protein and
the formulations require further verification before they can
be fully interpreted.
3.7. EXAFS Experiment. To obtain more detailed structural
information, Nb K-edge X-ray absorption near-edge struc-
ture (XANES) and extended X-ray absorption fine structure
(EXAFS) studies (Figure 7) were carried out. For these
studies, Nb-Fbp was prepared by treating apo-Fbp with
[Cp2Nb(OH)Cl2] (see experimental section).
The XANES edge position confirms the oxidation state
of the Nb as 5+. The Fourier transform shows two intense,
overlapping peaks at ca. 1.94 A˚ and 2.12 A˚, and a broader
peak at 3.3 A˚. The 1.94 A˚ and 2.12 A˚ peaks were simulated
with six oxygen atoms as back-scatters at two distances
(2 atoms at 1.94 A˚, and 4 atoms at 2.12 A˚). These result
from scattering from the atoms directly coordinated to the
NbV center and are likely to include tyrosinate, histidine,
glutamate, hydroxide, and oxo groups. ICP measurements
showed that phosphate was not present in this sample (data
not shown). Niobium-aryloxide bonds of 1.730–1.985 A˚ have
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Table 1: Analysis of the products from reactions of apo-Fbp with [Cp2Nb(OH)Cl2] and [Nb(NTA)2]−.
Reaction mixture(a) Product(b) Reaction mixture Product
[Cp2Nb(OH)Cl2]/[Fbp] [Nb]/[Fbp] [Nb(NTA)2]−/[Fbp] [Nb]/[Fbp]
1 : 1 0.86± 0.10 : 1 1 : 1 0.91± 0.10 : 1
20 : 1 2.23± 0.10 : 1 20 : 1 2.41± 0.10 : 1
(a) Reactions carried out for 48 hours in 10 mM HEPES buﬀer, pH 7.4, 310 K.
(a)Fbp concentration determined from A280.
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Figure 6: Characterization of Nbn-FBP (apo-Fbp reloaded with [Cp2Nb(OH)Cl2] (a) or [Nb(NTA)2] (b)) by chromatography on a MonoS
HR 5/5 column. The left axis shows the absorption profile at 280 nm, and the right axis is the percentage of buﬀer B (10 mM Hepes, 1 M
NaCl, pH7.5). Green line: gradient of the buﬀer B applied during the elution process; cyan line: absorbance at 280 nm.
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Figure 7: Nb K-edge X-ray absorption data. (a) EXAFS spectra, and (b) Fourier transform data for Nb-Fbp (prepared from 10 : 1
[Cp2Nb(OH)Cl2] : apoFbp reaction). Green line: experimental data; red line: calculated data.
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Table 2: Species detected by ESI-MS assay of products from the
reaction of [Nb(NTA)2]− or [Cp2Nb(OH)Cl2]with apo-Fbp.
Calcd/Da(a) Obsd/Da
Recombinant apo-Fbp with [Cp2Nb(OH)Cl2]
[a-Fbp] (33640) 33648
[aFbp + 4Cp2NbCl2] (34816) 34813
[aFbp + 4Cp2NbCl2+OH−] (34833) 34829
[aFbp + 4Cp2NbCl2+2OH−] (34850) 34842
[aFbp + 4Cp2NbCl2+3OH−] (33867) 34871
[aFbp + 4Cp2Nb(OH)Cl2] (34884) 34890
Recombinant apo-Fbp with [Nb(NTA)2]−
[aFbp + NH+4 ] (33657) 33655
[aFbp + 2Nb(NTA)2 + NTA + CH3COO−] (34835) 34837
[aFbp + 3Nb(NTA)2 + NTA] (34966) 34965
(a)The formulations are merely those which give reasonable fits to the
observed masses and cannot be interpreted as giving structural information
about the nature of the bound complexes. For example some sites could be
on the exposed surface of the protein as well as in the interdomain cleft.
previously been reported, including Nb-Ophenolate distances
of ca. 1.872 A˚ [36]. Thus the two shorter inner-sphere Nb-O
bonds in Nb-Fbp (1.94 A˚) are within the range of typical
Nb-O bonds assignable to the Nb-tyrosinate bonds but may
also be due to Nb=O double bonds and a possible bridging
oxo group. The Nb-O bond lengths are also similar to those
in known compounds such as (C2H6NO2)2[NbOF5] and
(C3H8-NO2)2[NbOF5]·2H2O [37], LiNbO(O-2,6-PhMe2)4P·
3THF, LiNbCl3(O-2,6-PhMe2)2P·2THF [38], NbCl3(3-[2,2′-
methylenebis(4,6-di-tert-butylphenol)-5-tert-butylsalicylid-
ene-(2,6-diisopropyl)phenylimine]) [34] and the [(Nb6Cl8O4)
Cl6] cluster. The Nb-Nb peak at 3.3 A˚ is similar to that
reported for the single Nb neighbor at 3.3 A˚ in a niobium-
peroxo-citrato complex [39]. The EXAFS data may be
consistent with the presence of a dinuclear Nb-O-Nb centre
in the adduct. No attempt was made to include Cp ligands in
a fit to the EXAFS data.
The EXAFS data do not allow an unambiguous assign-
ment of a structure to the bound niobium(V) dinuclear
centre since only averaged Nb–N/O bond lengths are
obtained and oxygen ligands cannot be distinguished from
nitrogen donors. One possibility is that the dinuclear centre
is anchored to the protein only by coordination to the two
active site Tyr residues, as are the clusters in previously
characterised Fe, Zr, and Hf complexes. The other ligands
for NbV may be oxygens from water or hydroxide without
coordination to the His or Glu sidechains which are ligands
in the mononuclear FeIII site.
4. Conclusions
Previous work has shown that eﬃcient iron acquisition is
required for the virulence of pathogenic bacteria and that
Fbp is one of the iron-uptake virulence genes [22, 30, 35, 40–
43]. The di-tyrosyl metal-binding motif in Fbp is highly
conserved and shows a strong binding ability with some
metals. Targetting this protein with an unnatural metal ion
such as niobium(V) which might block iron(III) uptake
therefore becomes a potential strategy for the design of novel
antibiotics.
Since the size of the binding cleft in Fbp is thought to be
matched to FeIII (ionic radius 0.69 A˚), previous studies have
shown similar tight binding between apoFbp and various
other metal ions such as TiIV (ionic radius 0.75 A˚), ZrIV
(ionic radius 0.86 A˚) and HfIV (ionic radius 0.85 A˚). Hence it
seemed reasonable to suppose that NbV (ionic radius 0.78 A˚)
might behave in a similar manner to these other metal ions.
As we expected, NbV from the [Nb(NTA)2]− and antitumor
complex [Cp2NbCl2]/[Cp2Nb(OH)Cl2] were readily taken
up into the specific iron sites of ferric iron binding protein.
The tight binding was confirmed by ICP-OES and ESI-
MS studies. Interestingly, kinetic studies showed that the
uptake of NbV by apo-Fbp is relatively rapid in vitro under
the conditions used, and titration studies monitored using
UV/vis also show that NbV can be displaced by FeIII, although
suggesting weaker binding of NbV. Structural studies using
EXAFS suggest the presence of a dinuclear Nb(V) centre
possibly with an Nb-O-Nb bridge, but further studies
are needed to define the conditions under which the Cp
ligands are displaced from Nb on binding to the protein.
These properties may allow NbV to bind strongly to Fbp
under certain environmental conditions. It would also be
interesting to investigate potential catalytic properties of such
a protein-bound dinuclear niobium centre. The recent novel
use of the metal complex desferrioxamine-gallium (DFO-
Ga) that targets P. aeruginosa iron metabolism and stops
biofilm formation [44], coupled with our work, suggests
that NbV complexes should be explored as potential novel
metalloantibiotics.
Acknowledgments
The authors thank the Wellcome Trust (Travelling Research
Fellowship awarded to Y. Shi) and Edinburgh Protein
Interaction Centre, the BBSRC, EPSRC, for their support
for this work. This paper is dedicated to Professor Nick
Hadjiliadis (University of Ioannina) on the occasion of his
retirement.
References
[1] H. Ko¨pf and P. Ko¨pf-Maier, “Titanocene dichloride—the first
metallocene with cancerostatic activity,” Angewandte Chemie
International Edition, vol. 18, no. 6, pp. 477–478, 1979.
[2] P. Ko¨pf-Maier, “Development of necroses, virus activation and
giant cell formation after treatment of Ehrlich ascites tumor
with metallocene dichlorides,” Journal of Cancer Research and
Clinical Oncology, vol. 103, no. 2, pp. 145–164, 1982.
[3] P. Ko¨pf-Maier, “Stage of pregnancy-dependent transplacental
passage of 195mPt after cis-platinum treatment,” European
Journal of Cancer and Clinical Oncology, vol. 19, no. 4, pp. 533–
536, 1983.
[4] P. Ko¨pf-Maier, “Tumor inhibition by titanocene complexes:
influence upon two xenografted human lung carcinomas,”
Journal of Cancer Research and Clinical Oncology, vol. 113, no.
4, pp. 342–348, 1987.
10 Bioinorganic Chemistry and Applications
[5] P. Ko¨pf-Maier, “Tumor inhibition by titanocene complexes:
influence on xenografted human adenocarcinomas of the gas-
trointestinal tract,” Cancer Chemotherapy and Pharmacology,
vol. 23, no. 4, pp. 225–230, 1989.
[6] P. Ko¨pf-Maier, “Antitumor activity of titanocene dichlo-
ride in xenografted human renal-cell carcinoma,” Anticancer
Research, vol. 19, no. 1A, pp. 493–504, 1999.
[7] P. Ko¨pf-Maier and H. Ko¨pf, “Antitumor metallocenes: new
developments and toxicologic features,” Anticancer Research,
vol. 6, no. 2, pp. 227–233, 1986.
[8] P. Ko¨pf-Maier and H. Ko¨pf, “Tumor inhibition by titanocene
complexes. Activity against B16 melanoma and colon 38
carcinoma,” Arzneimittel-Forschung, vol. 37, no. 5, pp. 532–
534, 1987.
[9] P. Ko¨pf-Maier, M. Leitner, R. Voigtla¨nder, and H. Ko¨pf,
“Molybdocen-dichlorid als antitumor-agens,” Zeitschrift fu¨r
Naturforschung C, vol. 34, no. 12, pp. 1174–1176, 1979.
[10] N. Kro¨ger, U. R. Kleeberg, K. Mross, L. Edler, G. Saß, and D.
K. Hossfeld, “Phase II clinical trial of titanocene dichloride in
patients with metastatic breast cancer,” Onkologie, vol. 23, no.
1, pp. 60–62, 2000.
[11] M. M. Harding and G. Mokdsi, “Antitumour metallocenes:
structure-activity studies and interactions with biomolecules,”
Current Medicinal Chemistry, vol. 7, no. 12, pp. 1289–1303,
2000.
[12] P. Ko¨pf-Maier and T. Kapo¨tke, “Antitumor activity of ionic
niobocene and molybdenocene complexes in high oxidation
states,” Journal of Cancer Research and Clinical Oncology, vol.
118, no. 3, pp. 216–221, 1992.
[13] P. Ko¨pf-Maier and H. Ko¨pf, “Non-platinum-group metal
antitumor agents: history, current status, and perspectives,”
Chemical Reviews, vol. 87, no. 5, pp. 1137–1152, 1987.
[14] P. Ko¨pf-Maier, M. Leitner, and H. Ko¨pf, “Tumor inhibi-
tion by metallocenes: antitumor activity of niobocene and
tungstocene dichlorides,” Journal of Inorganic and Nuclear
Chemistry, vol. 42, no. 12, pp. 1789–1791, 1980.
[15] M. M. Harding, M. Prodigalidad, and M. J. Lynch,
“Organometallic anticancer agents. 2. Aqueous chemistry
and interaction of niobocene dichloride with nucleic acid
constituents and amino acids,” Journal of Medicinal Chemistry,
vol. 39, no. 25, pp. 5012–5016, 1996.
[16] C. Ratledge, “Iron metabolism and infection,” Food and
Nutrition Bulletin, vol. 28, no. 4, supplement, pp. S515–S523,
2007.
[17] U. E. Schaible and S. H. E. Kaufmann, “Iron and microbial
infection,” Nature Reviews Microbiology, vol. 2, no. 12, pp.
946–953, 2004.
[18] I. J. Schalk, “Metal traﬃcking via siderophores in Gram-
negative bacteria: specificities and characteristics of the
pyoverdine pathway,” Journal of Inorganic Biochemistry, vol.
102, no. 5-6, pp. 1159–1169, 2008.
[19] A. J. Nowalk, S. B. Tencza, and T. A. Mietzner, “Coordination
of iron by the ferric iron-binding protein of pathogenic
Neisseria is homologous to the transferrins,” Biochemistry, vol.
33, no. 43, pp. 12769–12775, 1994.
[20] W. Zhong, D. Alexeev, I. Harvey, et al., “Assembly of an oxo-
zirconium(IV) cluster in a protein cleft,” Angewandte Chemie
International Edition, vol. 43, no. 44, pp. 5914–5918, 2004.
[21] W. Zhong, J. A. Parkinson, M. Guo, and P. J. Sadler,
“Unusual features for zirconium(IV) binding to human serum
transferrin,” Journal of Biological Inorganic Chemistry, vol. 7,
no. 6, pp. 589–599, 2002.
[22] H. Zhu, D. Alexeev, D. J. B. Hunter, D. J. Campopiano, and
P. J. Sadler, “Oxo-iron clusters in a bacterial iron-traﬃcking
protein: new roles for a conserved motif,” Biochemical Journal,
vol. 376, no. 1, pp. 35–41, 2003.
[23] M. Guo, I. Harvey, D. J. Campopiano, and P. J. Sadler,
“Short oxo-titanium(IV) bond in bacterial transferrin: a
protein target for metalloantibiotics,” Angewandte Chemie
International Edition, vol. 45, no. 17, pp. 2758–2761, 2006.
[24] C. Ferreiro´s, M. T. Criado, and J. A. Go´mez, “The neisserial
37 kDa ferric binding protein (FbpA),” Comparative Biochem-
istry and Physiology B, vol. 123, no. 1, pp. 1–7, 1999.
[25] P. Ellis, Studies of metalloproteins using EXAFS and XPD, Ph.D.
thesis, University of Sydney, Sydney, Australia, 1995.
[26] J. J. Rehr and R. C. Albers, “Scattering-matrix formulation of
curved-wave multiple-scattering theory: application to X-ray-
absorption fine structure,” Physical Review B, vol. 41, no. 12,
pp. 8139–8149, 1990.
[27] N. Binsted, EXCURV98: CCLRC Daresbury Laboratory Com-
puter Program, CCLRC Daresbury Laboratory, Warrington,
UK, 1998.
[28] L. Hedin, A. Johansso, Bi. Lundqvis, S. Lundqvis, and V.
Samathiy, “Eﬀects of electron-electron interaction on one-
electron properties of atoms and solids,” Arkiv fo¨r Fysik, vol.
39, no. 2, p. 97, 1969.
[29] J. J. Rehr, J. M. de Leon, S. I. Zabinsky, and R. C. Albers, “The-
oretical X-ray absorption fine structure standards,” Journal of
the American Chemical Society, vol. 113, no. 14, pp. 5135–5140,
1991.
[30] M. Guo, I. Harvey, W. Yang, et al., “Synergistic anion and
metal binding to the ferric ion-binding protein from Neisseria
gonorrhoeae,” Journal of Biological Chemistry, vol. 278, no. 4,
pp. 2490–2502, 2003.
[31] G. M. Then, H. Appel, J. Duﬃeld, D. M. Taylor, and W.-G.
Thies, “In vivo and in vitro studies of hafnium-binding to rat
serum transferrin,” Journal of Inorganic Biochemistry, vol. 27,
no. 4, pp. 255–270, 1986.
[32] M. Guo, H. Sun, H. J. McArdle, L. Gambling, and P. J. Sadler,
“Ti(IV) uptake and release by human serum transferrin and
recognition of Ti(IV)-transferrin by cancer cells: understand-
ing the mechanism of action of the anticancer drug titanocene
dichloride,” Biochemistry, vol. 39, no. 33, pp. 10023–10033,
2000.
[33] H. Sun, H. Li, and P. J. Sadler, “Transferrin as a metal ion
mediator,” Chemical Reviews, vol. 99, no. 9, pp. 2817–2842,
1999.
[34] C. M. Bruns, D. S. Anderson, K. G. Vaughan, et al.,
“Crystallographic and biochemical analyses of the metal-free
Haemophilus influenzae Fe3+-binding protein,” Biochemistry,
vol. 40, no. 51, pp. 15631–15637, 2001.
[35] D. Alexeev, H. Zhu, M. Guo, et al., “A novel protein-mineral
interface,” Nature Structural Biology, vol. 10, no. 4, pp. 297–
302, 2003.
[36] D. Homden, C. Redshaw, J. A. Wright, D. L. Hughes, and
M. R. J. Elsegood, “Early transition metal complexes bearing
a C-capped tris(phenolate) ligand incorporating a pendant
imine arm: synthesis, structure, and ethylene polymerization
behavior,” Inorganic Chemistry, vol. 47, no. 13, pp. 5799–5814,
2008.
[37] A. V. Gerasimenko, M. A. Pushilin, and R. L. Davi-
dovich, “Disordering of the [NbOF5]
2− complex anions
in bis(glycinium) pentafluoridooxidoniobate(V) and bis(β-
alaninium) pentafluoridooxidoniobate(V) dihydrate,” Acta
Crystallographica C, vol. 64, part 11, pp. m358–m361, 2008.
Bioinorganic Chemistry and Applications 11
[38] S. K. Park, S. M. Koo, and Y. E. Lee, “Heterometallic
lithium niobium complexes: synthesis and molecular struc-
tures of LiNbO(O-2, 6-PhMe2)4·3THF and [LiNbCl3(O-2,
6-PhMe2)2 · 2THF]2,” Polyhedron, vol. 19, no. 9, pp. 1037–
1041, 2000.
[39] M. K. Van Bael, I. Arcon, K. Van Werde, D. Nelis, J.
Mullens, and L. C. Van Poucke, “Structure determination by
EXAFS of Nb-peroxo-citrato complexes in aqueous solution-
gel systems,” Physica Scripta, vol. T115, pp. 415–417, 2005.
[40] M. Pintor, L. Ferro´n, J. A. Go´mez, A. Gorringe, M. T. Criado,
and C. M. Ferreiro´s, “Blocking of iron uptake by monoclonal
antibodies specific for the Neisseria meningitidis transferrin-
binding protein 2,” Journal of Medical Microbiology, vol. 45, no.
4, pp. 252–257, 1996.
[41] C. Ferreiro´s, M. T. Criado, and J. A. Go´mez, “The neisserial
37 kDa ferric binding protein (FbpA),” Comparative Biochem-
istry and Physiology B, vol. 123, no. 1, pp. 1–7, 1999.
[42] H. Boukhalfa, D. S. Anderson, T. A. Mietzner, and A. L.
Crumbliss, “Kinetics and mechanism of iron release from
the bacterial ferric binding protein nFbp: exogenous anion
influence and comparison with mammalian transferrin,”
Journal of Biological Inorganic Chemistry, vol. 8, no. 8, pp. 881–
892, 2003.
[43] J. A. Go´mez, M. T. Criado, and C. M. Ferreiro´s, “Bactericidal
activity of antibodies elicited against the Neisseria menin-
gitidis 37-kDa ferric binding protein (FbpA) with diﬀerent
adjuvants,” FEMS Immunology and Medical Microbiology, vol.
20, no. 1, pp. 79–86, 1998.
[44] E. Banin, A. Lozinski, K. M. Brady, et al., “The potential of
desferrioxamine-gallium as an anti-Pseudomonas therapeutic
agent,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 105, no. 43, pp. 16761–16766,
2008.
Submit your manuscripts at
http://www.hindawi.com
 Chromatography  
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Carbohydrate 
Chemistry
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com
International Journal of 
Analytical Chemistry
Volume 2013
ISRN 
Chromatography
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Bioinorganic Chemistry 
and Applications 
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Journal of
SPECTROSCOPY
ISRN 
Analytical 
Chemistry 
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Electrochemistry
International Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Advances in
Physical Chemistry
ISRN 
Physical Chemistry 
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Spectroscopy
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Inorganic Chemistry
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Journal of
Chemistry
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Inorganic Chemistry 
International Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
 International Journal ofPhotoenergy
Hindawi Publishing Corporation
http://www.hindawi.com
Analytical Methods 
in Chemistry
Journal of
Volume 2013
ISRN 
Organic Chemistry
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Catalysts
Journal of
